Boo-Hyon Kang

Statistics

Publications

Citations

206

H-Index

Active since

2009

Affiliations

National Cancer Institute(Current)

Pennsylvania State University

University of North Carolina at Chapel Hill

Texas A&M University

University of Nebraska Medical Center

Boo-Hyon Kang is an author at National Cancer Institute specializing in peroxisome proliferator-activated receptor signaling, peroxisome proliferator-activated receptors, and pharmacology.

Publications per year

2009–2021

Publications

Activation of Peroxisome Proliferator-Activated Receptor-β/δ (PPAR-β/δ) Inhibits Human Breast Cancer Cell Line Tumorigenicity

Pei‐Li Yao, José L. Quiles, Bokai Zhu et al. · Molecular Cancer Therapeutics · 2014 · 61 citations · Full text

Medicine, Oncology, Pharmacology +14

Differential Hepatic Effects of Perfluorobutyrate Mediated by Mouse and Human PPAR-α

Jennifer E. Foreman, Shu‐Ching Chang, David J. Ehresman et al. · Toxicological Sciences · 2009 · 44 citations

Life Sciences, Biochemistry, Pharmacology +17

Species Differences between Mouse and Human PPARα in Modulating the Hepatocarcinogenic Effects of Perinatal Exposure to a High-Affinity Human PPARα Agonist in Mice

Jennifer E. Foreman, Takayuki Koga, Oksana Kosyk et al. · Toxicological Sciences · 2021 · 25 citations · Full text

Medicine, Pharmacology, Toxicology +17

Chemoprevention of Chemically Induced Skin Tumorigenesis by Ligand Activation of Peroxisome Proliferator–Activated Receptor-β/δ and Inhibition of Cyclooxygenase 2

Bokai Zhu, Robert Bai, Mary J. Kennett et al. · Molecular Cancer Therapeutics · 2010 · 23 citations · Full text

Medicine, Dermatology, Pharmacology +16

Ligand activation of peroxisome proliferator-activated receptor-β/δ suppresses liver tumorigenesis in hepatitis B transgenic mice

Gayathri Balandaram, Lance R. Kramer, Boo-Hyon Kang et al. · Toxicology · 2016 · 18 citations

Medicine, Cancer Biology, Molecular Biology +14

1–5 of 7